Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5993 | Lys-Bradykinin |
| Endogenous bradykinin receptor agonist that displays some selectivity for the B2 receptor (Ki values are 2.54 and 0.63 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. Twice as potent as bradykinin in vivo. | |
| BCC5994 | [Lys5,MeLeu9,Nle10]-NKA(4-10) |
| Highy selective and potent NK2 receptor agonist (IC50 = 6.1 nM). Induces contraction of the rat fundus and bladder (EC50 values are 117 and 10 nM respectively). | |
| BCC5995 | [Phe8Ψ(CH-NH)-Arg9]-Bradykinin |
| Selective bradykinin B2 receptor agonist that is resistant to carboxypeptidase cleavage. 5-fold more potent and exhibits a more prolonged duration of action than bradykinin (Cat No. 3004) in vivo. | |
| BCC5996 | Sar-[D-Phe8]-des-Arg9-Bradykinin |
| Potent and selective bradykinin B1 receptor agonist (EC50 = 9.02 nM in rabbit aorta) that is resistant to aminopeptidase, kininase I and II (ACE) and neutral endopeptidase cleavage. Exhibits hypotensive and angiogenic activity in vivo. | |
| BCC5997 | Ac9-25 |
| N-terminal peptide of Annexin I (AI/Lipocortin I) that inhibits leukocyte extravasation. Acts as a formyl peptide receptor 1 (FPR1) ligand and stimulates neutrophil NADPH oxidase activation. | |
| BCC5998 | BIM 23042 |
| Selective neuromedin B receptor (NMB-R, BB1) antagonist (Ki values are 216 and 18,264 nM for BB1 and BB2 receptors respectively). Displays no activity at a range of other receptors. | |
| BCC5999 | TCS PrP Inhibitor 13 |
| Antiprion agent. Potently inhibits protease-resistant prion protein (PrP-res) accumulation in two types of prion-infected mouse neuroblastoma (N2a) cell lines (IC50 = 3 nM). | |
| BCC6001 | GLP-1 (9-36) amide |
| N-terminal truncated metabolite of glucagon-like peptide GLP-1-(7-36) formed by dipeptidyl peptidase-IV cleavage. Acts as an antagonist at the human GLP-1 receptor. Inhibits hepatic glucose production in vivo and is a weak insulinotropic agent. | |
